(Total Views: 569)
Posted On: 07/11/2020 5:22:26 PM
Post# of 148936
I don’t know where to get a copy of the study, but this is directly copied from Cytodyn’s website:
“ Leronlimab’s Clinical Trial Performance
CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients meeting its primary endpoint. 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/mL.”
It gives me confidence to see such a strong result, coupled with an even stronger safety profile. It’s also easier to take. Hope this helps until someone knows where to find the actual study.
“ Leronlimab’s Clinical Trial Performance
CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients meeting its primary endpoint. 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/mL.”
It gives me confidence to see such a strong result, coupled with an even stronger safety profile. It’s also easier to take. Hope this helps until someone knows where to find the actual study.
(0)
(0)Scroll down for more posts ▼
